EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study

Lenka Vanek iD, Amelie Kurnikowski, Simon Krenn, Sebastian Mussnig, Manfred Hecking iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15967 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Lenka Vanek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Kidney Failure, Chronic, Kidney Transplantation, Obesity. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vienna Science and Technology (WWTF) Precision Medicine Grant, Vienna Science and Technology Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chronic kidney disease (CKD) and obesity are major global health challenges, eventually leading to kidney replacement therapy (KRT), but body mass index (BMI) thresholds hinder kidney transplantation. Glucagon‐like peptide‐1 receptor agonists induce weight loss, thereby offering attractive treatment options; however, their safety and efficacy have not been systematically investigated in patients undergoing dialysis. Materials and Methods We conducted a prospective 12‐week, open‐label trial with 13 patients who had a BMI ≥ 30.00 kg/m 2 , were undergoing dialysis (12 haemodialysis and 1 peritoneal dialysis) and had not been listed for transplantation due to their weight. Semaglutide was administered once weekly subcutaneously, and the dose was increased from 0.25 mg to 0.5 mg and then to 1 mg. Study endpoints included change in body weight and BMI (primary – statistically evaluated by repeated measures analysis of variance [ANOVA]), side effects, adverse events, blood parameters and patient‐reported outcomes (secondary).

Results

At baseline, the mean age ± standard deviation of patients was 64.0 ± 6.4 years, the mean weight was 113.9 ± 16.6 kg, and the mean BMI was 37.3 ± 3.9 kg/m 2 . At week 12, average weight reduction under semaglutide treatment was 4.6 ± 2.4 kg and ranged from 2.0 to 9.7 kg ( p < 0.001 for weight and BMI reduction across the study period). One patient discontinued treatment due to nausea/vomiting, two patients died of unrelated causes and six patients reported side effects. Approximately 9 months after the treatment started, three patients were able to seriously reconsider being listed for transplantation.

Conclusions

Semaglutide treatment resulted in significant reduction in weight and BMI in patients with obesity undergoing dialysis, while maintaining an acceptable side effect profile comparable to that of the non‐dialysis population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesKidney Failure, ChronicKidney TransplantationObesityRenal DialysisAgedFemaleHumansMaleMiddle AgedBody Mass IndexHypoglycemic AgentsProspective StudiesTreatment OutcomeWeight LossSemaglutide

Stichwörter der Autor:innen

chronic kidney diseasedialysisgenderglucagon‐like peptide‐1 receptor agonistkidney failurenephrologyobesitysemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
  • Center for Public Health, Department of Epidemiology, Medical University of Vienna, Vienna, Austria.
  • AIT Austrian Institute of Technology GmbH, Center for Health and Bioresources, Medical Signal Analysis, Vienna, Austria.
  • Kidney Center, Kuratorium for Dialysis and Kidney Transplantation (KfH), Weiden, Germany.

ORCID-Profile: Lenka Vanek, Manfred Hecking

Förderung

  • Vienna Science and Technology (WWTF) Precision Medicine Grant
  • Vienna Science and Technology Fund

Zitieren

APA

Vanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024). Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15967

Vancouver

Vanek L, Kurnikowski A, Krenn S, Mussnig S, Hecking M. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15967

BibTeX
@article{Vanek2024,
  author = {Vanek, Lenka and Kurnikowski, Amelie and Krenn, Simon and Mussnig, Sebastian and Hecking, Manfred},
  title = {Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15967}
}
Kostenlos starten →